{"filing":{"accession_number":"0001213900-26-090182","cik":"0001851484","ticker":"CTOR","company_name":"CITIUS ONCOLOGY, INC.","form":"8-K","filing_date":"2026-08-14","report_date":"2026-08-14","primary_document":"ea0302226-8k_citius.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1851484/000121390026090182/ea0302226-8k_citius.htm"},"events":[{"id":27984,"run_id":25563,"accession_number":"0001213900-26-090182","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"On August 14, 2026, Citius Oncology, Inc. issued a press release announcing its results of operations for the third quarter of fiscal 2026, disclosing revenues of $1.5 million for Q3 2026 (compared to $0 in Q3 2025) and $7.1 million for the nine-month period, along with a net loss of $8.9 million for Q3 and condensed consolidated financial statements.","company_name":"CITIUS ONCOLOGY, INC.","ticker":"CTOR","filing_date":"2026-08-14","form":"8-K","submitted_at":null,"items":[{"id":29733,"accession_number":"0001213900-26-090182","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing fiscal Q3 2026 financial results for Citius Oncology. The filing explicitly states \"On August 14, 2026, Citius Oncology, Inc. issued a press release announcing our results of operations for the third quarter of fiscal 2026\" and includes condensed consolidated balance sheets and statements of operations showing revenues of $1.5M (Q3) and $7.1M (nine months), along with net losses. The press release is furnished as Exhibit 99.1 and is incorporated by reference, which is the standard format for earnings releases under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T20:45:11.499097+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29733,"accession_number":"0001213900-26-090182","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing fiscal Q3 2026 financial results for Citius Oncology. The filing explicitly states \"On August 14, 2026, Citius Oncology, Inc. issued a press release announcing our results of operations for the third quarter of fiscal 2026\" and includes condensed consolidated balance sheets and statements of operations showing revenues of $1.5M (Q3) and $7.1M (nine months), along with net losses. The press release is furnished as Exhibit 99.1 and is incorporated by reference, which is the standard format for earnings releases under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T20:45:11.499097+00:00","company_name":"CITIUS ONCOLOGY, INC.","ticker":"CTOR","filing_date":"2026-08-14"}]}